Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • Jennifer BoylstonEmail author
  • Charles Brenner
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_68


Historical Background

To date, approximately 80 common fragile sites (CFS) have been identified in the human genome (Ruiz-Herrera et al. 2006). Unlike rare fragile sites, which map to sites that are genetically altered in individuals, CFS occur at consistent genomic locations in particular cell types, which are defined by the paucity of replication initiation events at these loci (Letessier et al. 2011). DNA breaks at CFS, referred to as expression of the fragile site, can be induced via treatment with inhibitors of DNA replication, carcinogens, and environmental stresses (Lukusa and Fryns 2008). Several CFS colocalize with common deletions and translocations in tumors. Early efforts to find tumor suppressor genes encoded within fragile sites focused on FRA3Bat chromosomal location 3p14.2, the most frequently expressed human CFS. Perturbations at 3p14.2 had been noted in many cancers and the site includes the t(3;8) translocation breakpoint...

This is a preview of subscription content, log in to check access.


  1. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5?'-P1, P3-triphosphate hydrolase. Biochemistry. 1996;35(36):11529–35.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Brenner C. Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry. 2002;41(29):9003–14.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Campiglio M, Bianchi F, Andriani F, Sozzi G, Tagliabue E, Menard S, et al. Diadenosines as FHIT-ness instructors. J Cell Physiol. 2006;208(2):274–81.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Chaudhuri AR, Khan IA, Prasad V, Robinson AK, Luduena RF, Barnes LD. The tumor suppressor protein Fhit. A novel interaction with tubulin. J Biol Chem. 1999;274(34):24378–82.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979;301(11):592–5.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Draganescu A, Hodawadekar SC, Gee KR, Brenner C. Fhit-nucleotide specificity probed with novel fluorescent and fluorogenic substrates. J Biol Chem. 2000;275(7):4555–60.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA. 2001;98(13):7504–9.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA. 2001;98(6):3346–51.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Fisher DI, McLennan AG. Correlation of intracellular diadenosine triphosphate (Ap3A) with apoptosis in Fhit-positive HEK293 cells. Cancer Lett. 2008;259(2):186–91.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA. 2000;97(9):4742–7.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Glover TW, Hoge AW, Miller DE, Ascara-Wilke JE, Adam AN, Dagenais SL, et al. The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region. Cancer Res. 1998;58(15):3409–14.PubMedPubMedCentralGoogle Scholar
  12. Golebiowski F, Szulc A, Szutowicz A, Pawelczyk T. Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit. Arch Biochem Biophys. 2004;428(2):160–4.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Ishii H, Zanesi N, Vecchione A, Trapasso F, Yendamuri S, Sarti M, et al. Regression of upper gastric cancer in mice by FHIT gene delivery. FASEB J. 2003;17(12):1768–70.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–20.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Letessier A, Millot GA, Koundrioukoff S, Lachages AM, Vogt N, Hansen RS, et al. Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature. 2011;470(7332):120–3.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Lukusa T, Fryns JP. Human chromosome fragility. Biochim Biophys Acta. 2008;1779(1):3–16.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 2004;64(16):5745–52.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84(4):587–97.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Pace HC, Garrison PN, Robinson AK, Barnes LD, Draganescu A, Rosler A, et al. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci USA. 1998;95(10):5484–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Pace HC, Hodawadekar SC, Draganescu A, Huang J, Bieganowski P, Pekarsky Y, et al. Crystal structure of the worm NitFhit Rosetta stone protein reveals a Nit tetramer binding two Fhit dimers. Curr Biol. 2000;10(15):907–17.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Pekarsky Y, Campiglio M, Siprashvili Z, Druck T, Sedkov Y, Tillib S, et al. Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc Natl Acad Sci USA. 1998;95(15):8744–9.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Pichiorri F, Okumura H, Nakamura T, Garrison PN, Gasparini P, Suh SS, et al. Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions. J Biol Chem. 2009;284(2):1040–9.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Ruiz-Herrera A, Castresana J, Robinson TJ. Is mammalian chromosomal evolution driven by regions of genome fragility? Genome Biol. 2006;7(12):R115.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Saldivar JC, Shibata H, Huebner K. Pathology and biology associated with the fragile FHIT gene and gene product. J Cell Biochem. 2010;109(5):858–65.PubMedPubMedCentralGoogle Scholar
  25. Semba S, Han SY, Qin HR, McCorkell KA, Iliopoulos D, Pekarsky Y, et al. Biological functions of mammalian Nit1, the counterpart of the invertebrate NitFhit Rosetta stone protein, a possible tumor suppressor. J Biol Chem. 2006;281(38):28244–53.PubMedPubMedCentralCrossRefGoogle Scholar
  26. Shi Y, Zou M, Farid NR, Paterson MC. Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem J. 2000;352(Pt 2):443–8.PubMedPubMedCentralCrossRefGoogle Scholar
  27. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA. 1997;94(25):13771–6.PubMedPubMedCentralCrossRefGoogle Scholar
  28. Sun J, Okumura H, Yearsley M, Frankel W, Fong LY, Druck T, et al. Nit1 and Fhit tumor suppressor activities are additive. J Cell Biochem. 2009;107(6):1097–106.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Trapasso F, Krakowiak A, Cesari R, Arkles J, Yendamuri S, Ishii H, et al. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc Natl Acad Sci USA. 2003;100(4):1592–7.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Trapasso F, Pichiorri F, Gaspari M, Palumbo T, Aqeilan RI, Gaudio E, et al. Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem. 2008;283(20):13736–44.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA. 2001;98(18):10250–5.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Biochemistry and Program in Molecular and Cellular BiologyCarver College of Medicine, University of IowaIowa CityUSA